Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $283 | In Stock | |
5 mg | $742 | In Stock | |
10 mg | $1,190 | In Stock | |
25 mg | $1,770 | In Stock | |
50 mg | $2,380 | In Stock |
Description | Ociperlimab (BGB-A1217) is a humanized antibody targeting TIGIT with antitumor activity. It blocks the TIGIT-PVR interaction and is used in the study of advanced solid tumors. |
Targets&IC50 | TIGIT:0.135 nM (Kd) |
In vitro | Treatment with Ociperlimab (0-10 μg/mL) increased the secretion of IFN-γ by cytomegalovirus-specific T cells. Ociperlimab (1-1000 ng/mL) activates natural killer cells and monocytes in an FC-dependent manner. Ociperlimab removes TIGIT from the surface of T cells through FC-dependent endocytosis in vitro. [1] |
In vivo | Ociperlimab (3 and 10 mg/kg; Intrabitoneal injection) in CT26 WT tumor-bearing human TIGIT knockout mice and MC38 tumor-bearing human TIGIT knockout mice showed that Ociperlimab produced anti-tumor effects in an FC-dependent manner. [1] |
Alias | WCD-118, WCD118, BGB-A1217, BGBA1217 |
Cas No. | 2342597-93-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.